Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adagene Inc ADR
(NQ:
ADAG
)
2.210
-0.060 (-2.64%)
Streaming Delayed Price
Updated: 3:57 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adagene Inc ADR
< Previous
1
2
3
4
Next >
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
September 16, 2024
Via
Benzinga
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
September 16, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Participate in Investor Conferences in September
August 29, 2024
From
Adagene Inc.
Via
GlobeNewswire
How Is The Market Feeling About Adagene?
January 18, 2024
Via
Benzinga
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
July 25, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
July 12, 2024
From
Adagene Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
May 31, 2024
Via
Benzinga
Adagene to Present at Investor Conferences in June
May 22, 2024
From
Adagene Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
April 01, 2024
Via
Benzinga
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
March 29, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
March 07, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
February 27, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic
February 09, 2024
From
Adagene Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
February 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
January 22, 2024
Via
Benzinga
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
January 20, 2024
Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech...
Via
Talk Markets
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 19, 2024
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 17, 2024
Via
Benzinga
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 17, 2024
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 17, 2024
Via
Benzinga
Why Is Cancer Focused Adagene Stock Plummeting Today?
January 17, 2024
Adagene presents results at ASCO 2024 Gastrointestinal Cancers Symposium. ADG126, combined with Merck's Keytruda, shows limited toxicity, sustained partial responses, and a 22% overall response rate in...
Via
Benzinga
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
January 17, 2024
Shares of DatChat, Inc. (NASDAQ: DATS) fell sharply in pre-market trading after announcing a proposed underwritten public offering of common stock. DatChat shares dipped 33.1% to $2.13 in pre-market...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 17, 2024
It's time for a breakdown of the biggest pre-market stock movers for Wednesday morning as we check out all of the latest news today!
Via
InvestorPlace
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
January 16, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
January 04, 2024
From
Adagene Inc.
Via
GlobeNewswire
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
November 03, 2023
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 12, 2023
From
Adagene Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
October 06, 2023
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.